Researchers at the RIKEN Center for Developmental Biology (CDB) have successfully transplanted retinal pigment cells derived from stem cells of one monkey into the eyes of other monkeys without rejection and without the need for immunosuppressant drugs. Published in Stem Cell Reports, the study shows that this procedure is possible as long as a set of cells called the MHC are genetically matched between the host monkey and the new retinal cells.
A realistic hope of modern medicine is to replace damaged tissue with healthy cells grown in the lab. Currently, adult cells can be reprogrammed into stem cells, and then re-differentiated and grown into desired cell types. The researchers at RIKEN CDB led by Masayo Takahashi have already begun a clinical transplant trial in people with age-related macular degeneration. The team grew retinal pigment cells from induced pluripotent stem cells (iPSCs) and transplanted them into the damaged retina of a human participant. In order to avoid tissue rejection, they used autologous iPSCs—iPSCs that were created from the recipient’s own skin cells.
While this method is sound, producing autologous iPSCs is costly. Additionally, because the cells must grow at the same rate as they do during normal development, a person would have to wait more than a year before a transplant could be performed.
Notes lead author Sunao Sugita, “In order to make iPSC transplantation a practical reality, the current goal is to create banks of iPSC-derived tissues that can be transplanted into anyone as they are needed. However, immune responses and tissue rejection are big issues to overcome when transplanting tissue derived from other individuals.”
The new study tested a technique called MHC matching as a way to overcome this issue. Major histocompatibility complexes (MHCs) are a sets of cell-surface proteins found in all cells that function in the immune system. In humans, MHCs are also called human leukocyte antigens (HLAs). There are many genetic variations of MHCs, and after transplantation, if the MHCs of the transplanted cells are not recognized by the T cells of the host immune system, there is an immune response and the tissue is rejected.
To test whether MHC matching is a viable method, the team used retinal pigment cells that were grown from monkey iPSCs in the iPS cell bank at the Center for iPS Cell Research and Application, Kyoto University. They transplanted the cells into the subretinal space in monkeys with either genetically matched or non-matched MHCs.
The researchers found that these transplanted cells survived without rejection for at least 6 months in MHC-matched monkeys, without using any of the usually necessary immunosuppressant drugs. In contrast, rejection was relatively quick in the MHC-mismatched monkeys. Immunohistochemical examination showed that infiltration by inflammatory cells was only present in the transplanted grafts of MHC-mismatched monkeys. In vitro, the team saw that T cells failed to respond to the iPSC-derived retinal pigment cells if they were from an MHC-matched monkey.
In a separate study published in the same issue of Stem Cell Reports, the researchers saw similar results when they repeated this last experiment with human T cells and HLA-matched or unmatched retinal pigment cells grown from IPSCs.
Now that we have established the lack of immune response in monkeys and in human cells in vitro,” explains Sugita, “using the iPS cell bank appears to be a viable solution, at least in the case of retinal pigment epithelial cell transplantation.”
“In the next clinical trial,” continues Sugita, “we plan to use allogeneic iPS-retinal pigment epithelial cells from HLA homozygote donors. The clinical data after the transplantation will allow us to see if the iPS cell bank is truly useful or not. If so, I think this type of transplantation can become standard treatment within 5 years.”
The Latest on: iPSC transplantation
The Latest on: Biomechanics
via Google News
The Latest on: iPSC transplantation
- Transplanting iPSC Derived Neural Stem Cells into the Cerebral Cortex of Neonatal Ratson November 18, 2019 at 5:12 am
This article outlines how to perform transplantation of Axol Human iPSC-Derived Neural Stem Cells into a neonatal (0 to 2 days old) rat host. The cell survival of Axol hNSCs into neonatal hosts is ...
- Fate Therapeutics Inc (FATE) Q3 2019 Earnings Call Transcripton November 5, 2019 at 6:31 pm
FT516 is the second product candidate emerging from our iPSC product platform and it is the first ever cell product in the ... candidate for the prevention of acute graft versus host disease in ...
- Transplantation of Mouse Induced Pluripotent Stem Cell-Derived Podocytes in a Mouse Model of Membranous Nephropathy Attenuates Proteinuriaon October 29, 2019 at 3:05 am
Thus, there is hope that generation and transplantation of podocytes from induced pluripotent stem cells (iPSCs), could potentially be used as a curative treatment for glomerulonephritis caused by ...
- First-ever US clinical trial of engineered iPSC-derived cell therapy for blood canceron October 28, 2019 at 12:17 pm
The first-of-its-kind NK cell cancer immunotherapy, called FT516, is manufactured from a human induced pluripotent stem cell (iPSC) that has been genetically engineered to enhance ... and the medical ...
- Using iPSC Techniques to Study Genetics, Mechanisms & Treatments of Neurodegenerative Disorderson October 27, 2019 at 9:04 pm
Furthermore, glial transplantation also slowed disease progression and increased lifespan in rodent models. iPSC-based glial replacement may therefore be an important therapeutic strategy than ...
- Engineering biomimetic microvascular meshes for subcutaneous islet transplantationon October 16, 2019 at 6:30 am
When the scientists similarly attached the iPSC-EC mesh to a diffusion chamber containing rat islets to support the islets. The mesh group led to significantly better diabetes control compared to the ...
- Tissue Transplantation Products and Services Market Set for Rapid Growth and Trend, by 2026on October 15, 2019 at 2:41 am
Autologous stem cell transplant has become convenient mainly due to advent of induced pluripotent stem cells (iPSC). Scientists are trying to develop organs from human induced pluripotent stem cells ...
- Woman Receives First Corneal Transplant Made from iPS Cellson September 3, 2019 at 1:48 pm
Currently, around 1,600 people are on the wait list for such a procedure in Japan, according to The Japan Times, and a 2016 JAMA Ophthalmology survey estimates that 12.7 million people are in need of ...
- New Clues on Stem Cell Transplant Rejection Revealed in Studyon August 19, 2019 at 9:13 am
so it’s critical that iPSC and stem cell products used therapeutically are screened for mitochondrial mutations prior to transplant.” Funding: The study was supported by research grants from the ...
via Bing News